Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Acupuncture for the treatment of severe acute pain in Herpes Zoster: results of a nested, open-label, randomized trial in the VZV pain study
Ursini T, Tontodonati M, Manzoli L, Polilli E, Rebuzzi C, Congedo G, di Profio S, Toro PM, Consorte A, Placido G, Lagana S, d'Amario C, Granchelli C, Parruti G, Pippa L, The VZV Pain Study Group
BMC Complementary and Alternative Medicine 2011 Jun 5;11(46):Epub
clinical trial
5/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: Yes; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: No; Adequate follow-up: No; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

BACKGROUND: Data on the potential efficacy of acupuncture (AC) in controlling intense or very intense pain in patients with Herpes Zoster (HZ) has not been so far adequately assessed in comparison with standard pharmacological treatment (ST) by a controlled trial design. METHODS: Within the VZV Pescara study, pain was assessed in HZ patients on a visual analogue scale (VAS) and by the McGill Pain Questionnaire (MPQ) both at the beginning and at the end of treatment. Response rates, mean changes in pain intensity, differences in total pain burden with an area-under-the-curve (AUC) method over a 1-year follow-up and differences in the incidence of Post-Herpetic Neuralgia (PHN) were evaluated. RESULTS: One hundred and two patients were randomized to receive either AC (n = 52) or ST (n = 50) for 4 weeks. Groups were comparable regarding age, sex, pain intensity at presentation and missed antiviral prescription. Both interventions were largely effective. No significant differences were observed in response rates (81.6% versus 89.2%, p = 0.8), mean reduction of VAS (4.1 +/- 2.3 versus 4.9 +/- 1.9, p = 0.12) and MPQ scores (1.3 +/- 0.9 versus 1.3 +/- 0.9, p = 0.9), incidence of PHN after 3 months (48.4% versus 46.8%, p = 0.5), and mean AUC during follow-up (199 +/- 136 versus 173 +/- 141, p = 0.4). No serious treatment-related adverse event was observed in both groups. CONCLUSIONS: This controlled and randomized trial provides the first evidence of a potential role of AC for the treatment of acute herpetic pain. TRIAL REGISTRATION: ChiCTR-TRC-10001146.

Full text (sometimes free) may be available at these link(s):      help